Q4 profit grows 40%, full-year net nearly doubles - CNBC TV18

Natco Pharma Ltd on Friday (May 27) reported a 40.1% year-on-year (YoY) jump in net profit at ₹386.3 crore for the fourth quarter that ended March 31, 2024.

NSE

In the corresponding quarter last fiscal, Natco Pharma posted a net profit of ₹275.8 crore, the company said in a regulatory filing. The company's revenue from operations increased 19% to ₹1,068.3 crore against ₹898 crore in the year-ago period.

At the operating level, EBITDA rose 46.6% to ₹497.3 crore in the fourth quarter of this fiscal over ₹339.2 crore in Q4 of FY23. The EBITDA margin stood at 46.6% in the reporting quarter versus 37.8% in the corresponding period in the previous fiscal. EBITDA is earnings before interest, tax, depreciation, and amortisation.

Also Read: DCM Shriram Q4 Results | Net profit rises 23%, revenue dips 5%

FY24

The company has recorded consolidated total revenue of ₹4,126.9 crore for the year ended March 31, 2024, against ₹2,811.7 crore for the last year, reflecting 46.8% growth. The net profit for the period, on a consolidated basis, was ₹1,388.3 crore versus ₹715.3 crore last year, showing a growth rate of 94.1%.

Charges

On the domestic business front, the company has taken a one-time charge of approximately ₹90 crore, which is reflected in revenue and profitability numbers. On the crop health sciences (CHS) business, due to a poor crop season, the stock returns amounted to ₹25 crore more than was expected. Provisions on assets of the CHS division amounted to about ₹30 crore.

Also Read: NTPC Q4 Results | Net profit dips 2% to ₹5,556 crore, declares dividend of ₹3.25

The results came after the close of the market hours. Shares of Natco Pharma Ltd ended at ₹1,028, up by ₹7.50, or 0.73%, on the BSE.